The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
November 28th 2024
Rising health care costs and the complex nature of medication management have prompted PBMs to adopt AI tools to enhance patient outcomes, streamline claims processes, reduce waste, and design smarter, data-driven health plans.
New Federal Primary Care Payment Models: Another Step Toward Value Based Care
April 22nd 2019The Center for Medicare and Medicaid Innovation (CMMI) will be inviting primary care practices to participate in 5 new alternative payment models that will allow primary care practices to provide new types of services to their patients that are not supported by current Medicare payments.
Read More
FDA Approves Pembrolizumab Combo Therapy for Advanced Renal Cell Carcinoma
April 22nd 2019Pembrolizumab (Keytruda, Merck) has received FDA approval as a first-line treatment in combination with axitinib (Inlyta) for patients with advanced renal cell carcinoma (RCC), making it the first indication for pembrolizumab in this patient population.
Read More
Study Shows Precancerous Cervical Lesions Have Declined
April 22nd 2019Precancerous cervical lesions, known as high-grade cervical lesions (CIN2+) can develop a few years after infection and have been used to monitor human papillomavirus (HPV) vaccine impact since cancers can take decades to develop.
Read More
Hormone Therapy Combination Now Available for Treating Hot Flashes in Menopausal Women
April 18th 2019The commercial availability of Bijuva offers an FDA approved alternative to marketed synthetic hormones or individual estrogen and progesterone products that have not been FDA-approved for combination use.
Read More
Robust Responses Found in 20-Serotype Pneumococcal Vaccine Trial
April 17th 2019The study presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands was a phase 2 randomized, active-controlled, double-blinded trial (N=444). All participants were ages 60 to 64 years.
Read More
New Treatment for Osteoporosis In Postmenopausal Women is Available
April 16th 2019Approved by the FDA on April 9, 2019, Amgen’s romosozumab-aqqg therapy (Evenity) is indicated for osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Read More
Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval
April 16th 2019Estimates suggest that by 2020, 1.5 to 1.75 million people in the U.S. will be living with wet AMD, a leading cause of blindness worldwide and a rapidly growing public health concern, according to Novartis.
Read More
Plants May Offer Prevention Benefits for Vision Loss in Patients with Diabetes
April 12th 2019A study, which tested naturally occurring homoisoflavonoids found in the Hyacinthaceae plant family and their synthetic derivatives, focused on the abnormal growth of new blood vessel cells in the eye that are linked to types of blindness.
Read More